Kosugi S, Akamizu T, Takai O, Prabhakar B S, Kohn L D
Cell Regulation Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Thyroid. 1991 Winter;1(4):321-30. doi: 10.1089/thy.1991.1.321.
The possibility that thyroid-stimulating antibodies (TSAbs) might interact with receptor determinants different from those important for high affinity TSH binding has been evaluated. Deletion mutants of the extracellular domain of the rat TSH receptor as well as point mutations of potential N-linked glycosylation sites were created. TSH binding and the ability of TSH or a TSAb to increase cAMP levels after transfection in Cos-7 cells were then measured. Mutation of two glycosylation sites (residues 77 and 198) was shown to significantly decrease high affinity TSH binding but not the activity of a TSAb. A third glycosylation site mutant (residue 302) was identified that enhanced TSAb activity but had no effect on high affinity TSH binding, and a deletion mutant (residues 308-410) lost TSAb activity but preserved TSH binding. The last two mutations are within a region having low homology with gonadotropin receptors. This same region has, in addition, a determinant that is not important for receptor activity, yet is reactive with Graves' IgG. Thus, a deletion of residues 339-367 has no effect on TSH binding or TSH/TSAb activity, yet contains a peptide (residues 352-367) reactive in ELISA assays with IgG from greater than 80% of Graves' patients but not with IgG from normal individuals, patients with nonautoimmune thyroid disease, or patients with autoimmune disease not related to the thyroid. We, therefore, identify different receptor determinants for TSAb and high affinity TSH binding, consistent with predictions from TSH receptor monoclonal antibody studies. In addition, we identify a receptor peptide that is reactive with TSH receptor antibodies in Graves' patients, despite its having no determinants important for TSH or autoantibody activity in functional assays.
促甲状腺素抗体(TSAbs)可能与不同于那些对高亲和力促甲状腺素(TSH)结合重要的受体决定簇相互作用,这种可能性已得到评估。构建了大鼠TSH受体细胞外结构域的缺失突变体以及潜在N-连接糖基化位点的点突变体。然后测量了在Cos-7细胞中转染后TSH的结合情况以及TSH或TSAb增加环磷酸腺苷(cAMP)水平的能力。两个糖基化位点(第77和198位残基)的突变显示显著降低高亲和力TSH结合,但不影响TSAb的活性。鉴定出第三个糖基化位点突变体(第302位残基),其增强了TSAb活性,但对高亲和力TSH结合无影响,并且一个缺失突变体(第308 - 410位残基)丧失了TSAb活性但保留了TSH结合能力。最后两个突变位于与促性腺激素受体具有低同源性的区域内。此外,这个相同区域有一个对受体活性不重要但与格雷夫斯病(Graves')IgG反应的决定簇。因此,第339 - 367位残基的缺失对TSH结合或TSH/TSAb活性没有影响,但包含一个在酶联免疫吸附测定(ELISA)中与超过80%格雷夫斯病患者的IgG反应但不与正常个体、非自身免疫性甲状腺疾病患者或与甲状腺无关的自身免疫性疾病患者的IgG反应的肽(第352 - 367位残基)。因此,我们确定了TSAb和高亲和力TSH结合的不同受体决定簇,这与TSH受体单克隆抗体研究的预测一致。此外,我们鉴定出一个在格雷夫斯病患者中与TSH受体抗体反应的受体肽,尽管其在功能测定中没有对TSH或自身抗体活性重要的决定簇。